TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with histologically documented locally advanced (tumor \[T\] 4b, any node \[N\]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract~* Participants with measurable and/or non-measurable disease according to RECIST v1.1~* Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract~* If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted~* Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2~Exclusion Criteria:~* Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract~* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation~  1. Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible~ 2. Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible~* Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1~* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol~* Significant renal disorder indicating a need for renal transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (Type: EXPERIMENTAL): Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Female and/or male healthy Chinese subjects aged between 18 and 55 inclusive who reside in Hong Kong~3. Ability to have repeated blood draws or effective venous catheterization~4. Willing to consume food and beverages using a standardized daily diet containing 40 (± 10%) mEq/day sodium and 128 (± 10%) mEq/day potassium provided by the research site~Key Exclusion Criteria:~1. Participation in another clinical study with an investigational product during the last 3 months~2. Subjects who were receiving concomitant medications including vitamins, dietary supplements and herbal preparations within 2 weeks prior to Study Day 1 of the Diet Run-in Period.~3. Current and/or past history of alcohol abuse within the past year or a positive results (exceed normal range) of breath test for alcohol abuse~4. Current and/or past history of drugs abuse within the past year or a positive drug abuse screen, e. g. methylenedioxymethamphetamine, opiate, barbiturates, benzodiazepines, ketamine, cocaine, amphetamine, methamphetamine, marijuana, and methadone.~5. Plasma donation within 1 month of screening or any blood donation/blood loss \>500 mL during the 3 months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ZS 5g, qd (Type: EXPERIMENTAL): Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
- ZS 10g, qd (Type: EXPERIMENTAL): Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria~* Have a length of disease duration, from first symptom, of less than (\<) 10 years~* Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy~* Suboptimal disease control while on a DMT~* Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening~* For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug~Exclusion Criteria:~* Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)~* Inability to complete an Magnetic Resonance Imaging (MRI) procedure~* Known presence of other neurological disorders~* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study~* History or currently active primary or secondary immunodeficiency~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* History of opportunistic infections~* History or known presence of recurrent or chronic infection~* History of malignancy~* Congestive heart failure~* Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ocrelizumab (Type: EXPERIMENTAL): Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18, with chronic genotype 1 HCV infection~* HCV treatment-naive~* HCV RNA \> 10,000 IU/mL at screening~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Presence of cirrhosis~* Coinfection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 8 Week (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 8 weeks.
- LDV/SOF+RBV 8 Week (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
- LDV/SOF 12 Week (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a pre-operative American Society of Anesthesiology Physical Status I, II, or III (Class I are healthy persons less than 80 years of age, Class II are patients over age 80 years of age with mild systemic disease, and Class III are patients with severe and non-incapacitating disease)~* Admitted to the Post-Anesthesia Care Unit after general anesthesia or spinal/epidural anesthesia using short-acting agents~* Having had one of these surgical procedures: small and large bowel resections with anastomosis, colectomy, enterolysis, sigmoidectomy, closure of enteric fistulae, repair of cecal or sigmoid volvulus, lower anterior resection, stoma closure, bariatric surgery, liver resection, splenectomy, gastrectomy, fundoplication, total abdominal hysterectomy, total vaginal hysterectomy, anterior-posterior repair, oophorectomy, or myomectomy and cystectomy~* Awake and breathing spontaneously with a respiratory rate of 8 to 24 breaths per minute and oxygen saturation of 90% or higher (with or without supplemental oxygen)~* Expected to remain hospitalized for at least 24 hours postoperatively~Exclusion Criteria:~* Patients whose postoperative pain would normally be managed with oral or non-narcotic pain medication~* Who received long-acting intraoperative epidural, spinal anesthesia, or local anesthetics in the surgical area, or who are expected to have postoperative analgesia supplied by a continuous regional technique or patient-controlled epidural analgesia~* Have a history of allergy, hypersensitivity, or tolerance to fentanyl or morphine, have a history of allergy or hypersensitivity to cetylpyridinium chloride or skin adhesives, or have the presence of active skin disease that would interfere with application of the E-TRANS fentanyl system~* Who received steroids within 1 month before surgery or during surgery~* Expected to require intensive care postoperatively or who will probably need additional surgical procedures within 72 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is Japanese.~* Smoking, healthy subject as judged by the Investigator.~* Subject smokes at least 10 commercially available non-menthol CCs per day (no brand restrictions) for the last 4 weeks, based on self reporting.~* Subject has smoked for at least the last 3 consecutive years.~* Subject does not plan to quit smoking in the next 3 months.~Exclusion Criteria:~* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).~* The subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.~* For women: Subject is pregnant or is breast feeding.~* For women: Subject does not agree to use an acceptable method of effective contraception.

- Gender: ALL
- Minimum Age: 23 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tobacco Heating System (THS 2.2) (Type: EXPERIMENTAL): Ad libitum use of THS 2.2 for 5 days in confinement
- Smoking abstinence (SA) (Type: SHAM_COMPARATOR): Abstinence from smoking for 5 days in confinement
- Conventional cigarette (CC) (Type: ACTIVE_COMPARATOR): Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB/IV or Relapsed NSCLC~* Age \>= 18 years~* At least one measurable lesion by RECIST (version 1.1)~* ECOG PS 0, 1, 2~* Hematologic profile~  * Hgb \> 8 g/dL, ANC \>= 2,000/m3, Platelet \>= 100,000/m3~* Hepatic profile~  * Total bilirubin \<= 1.5 x upper normal value~ * Transaminases \<= 3 x upper normal value \<= 5 x upper normal value in case of liver metastasis~* Creatinine \<= 1.5mg/dL~* Patients should be recovered from toxicities of previous treatment.~* Written informed consent by patient or surrogates~Exclusion Criteria:~* Patients who had been previously treated with chemotherapy for NSCLC~* Active infection requiring antibiotics treatment~* Prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix~* Peripheral neuropathy \>= grade 2 by NCI CTCAE 4.0~* Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable angina, Congestive heart failure \>= NYHA grade 2 Uncontrolled significant arrhythmia~* Patients who entered other clinical trials within 4 weeks~* Pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belotaxel plus Belloxa (Type: EXPERIMENTAL): Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DTaP and Apnea/Bradycardia in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Born at a gestational age \< 37 weeks.~* Still in the hospital at time of study.~* Between 56 - 60 days chronological age.~Exclusion Criteria:~* Had active infections, were critically ill, or had unstable vital signs.~* Requiring assisted ventilation or tracheostomy during the study.

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 60 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets high risk or at potential risk for tumor lysis syndrome (TLS):~   A patient is at high risk for TLS if he/she presents with:~  * Hyperuricemia of malignancy (plasma uric acid \> 7.5 mg/dL);~  * A diagnosis of very aggressive lymphoma/leukemia based on the Revised European-American Lymphoma (REAL) classification of lymphoma/leukemia;~  * Acute myeloid leukemia (AML);~  * Chronic myeloid leukemia (CML) in blast crisis; or~  * High grade myelodysplastic syndrome (refractory anemia with excess blast, chronic myelomonocytic leukemia, and refractory anemia with excess blast in transformation) only if they have \> 10% bone marrow blast involvement and are given aggressive treatment similar to AML.~   A patient is at potential risk for TLS if he/she presents with:~  * A diagnosis of aggressive lymphoma/leukemia based on the REAL classification of lymphoma/leukemia plus 1 or more of the following criteria:~     * Lactate dehydrogenase (LDH) \>= 2 x upper limit of normal (ULN) (IU/L)~    * Stage III-IV disease~    * Stage I-II disease with at least 1 lymph node/tumor \> 5 cm in diameter~   In addition to the above-mentioned eligibility criteria, the patients should have the following criteria:~2. Eastern Cooperative Oncology Group (ECOG) performance status 0-3~3. Age \>= 18 years~4. Life expectancy \> 3 months~5. Negative pregnancy test (females of child bearing potential) and use of effective contraceptive method (for both males and females). A pregnancy test may be performed on serum or urine human chorionic gonadotropin (HCG).~6. Signed written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Rasburicase alone given as a single agent for 5 days
- Arm B (Type: EXPERIMENTAL): Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
- Arm C (Type: ACTIVE_COMPARATOR): Oral allopurinol alone given as a single agent for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Consenting patients fulfilling the Poser's clinical criteria for definite MS~2. Age: 18-65, males and females~3. Duration of disease: \>3 years~4. Progressive form of MS: PPMS, SPMS (with/without relapses)~5. EDSS score of 3.5 - 6.5~6. Failure to currently available, registered - first and second line immunomodulatory treatments (at least one).~7. Evidence for new activity of MS during the 3 months before the injection of MSC.~Exclusion Criteria:~1. Patients who were treated with cytotoxic medications during the last 3 months prior to the inclusion.~2. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results~3. Patients with active infections~4. Patients with severe cognitive decline or inability to understand and sign the informed consent~5. Patients who received any cellular treatment in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IT- Treated (Type: EXPERIMENTAL): Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
- IV - Treated (Type: EXPERIMENTAL): Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of Alcohol Use on Chronic Orofacial Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive diagnosis of jaw pain, including temporomandibular joint and muscle disorder (TMD) (jaw pain group only)~* Consume at least 1 drink/month over the past 6 months~Exclusion Criteria:~* History of chronic pain other than jaw pain or TMD~* Current use of opioids~* Current major depression~* History of any psychotic disorder~* Undercontrolled hypertension or diabetes~* History of neurologic disease~* History of serious medical illness~* History of drug or alcohol dependence, including nicotine, or a pattern of hazardous alcohol use

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Jaw pain patients (Type: EXPERIMENTAL): Individuals seeking care for jaw pain, including temporomandibular joint and muscle disorder (TMD).
- Healthy controls (Type: EXPERIMENTAL): Healthy social drinkers without jaw pain recruited as a comparison group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria~* Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at baseline~Exclusion Criteria:~* Primary progressive multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
- Ozanimod1 mg (Type: EXPERIMENTAL): Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
- Interferon β-1a (Type: ACTIVE_COMPARATOR): interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete